title: Association between toll-like receptor expression and human papillomavirus type 16 persistence.
abstract: The mechanisms involved in mucosal immune control of cervical human papillomavirus (HPV) infection remain ill defined. Because toll-like receptors (TLRs) are key players in innate immune responses, we investigated the association between TLR expression and viral persistence or clearance in young women with incident infections with oncogenic HPV types 16 or 51. Messenger RNA expression of TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8 and TLR9 was measured by quantitative reverse transcription-PCR using human endocervical specimens, collected before and after viral acquisition, in a cohort well characterized for HPV infections. Wilcoxon rank sum test was used to compare the change seen from preinfection to incident infection between women who subsequently cleared infection with those who did not. HPV 16 infections that cleared were significantly (p < 0.05) associated with an increase in expression of the four viral nucleic acid-sensing TLRs (TLR3, TLR7, TLR8 and TLR9) as well as TLR2 upon viral acquisition. Similar associations were not observed for HPV 51. In women who subsequently cleared their HPV 16 infection, changes in TLR1, TLR3, TLR7 and TLR8 expression levels between preincident and incident visits were significantly correlated with parallel changes in the levels of interferon-α2, measured by immunoassay in cervical lavage specimens. This study suggests that dampened TLR expression in the cervical mucosa is a type-specific mechanism by which HPV 16 interferes with innate immune responses, contributing to viral persistence, and that TLR upregulation and resultant cytokine induction is important in subsequent viral clearance.
authors.affiliation: Infectious Disease Research Training Program, University of California, San Francisco, CA 94118, USA.
authors.forename: Ibrahim I
authors.initials: II
authors.lastname: Daud
authors.forename: Mark E
authors.initials: ME
authors.lastname: Scott
authors.forename: Yifei
authors.initials: Y
authors.lastname: Ma
authors.forename: Stephen
authors.initials: S
authors.lastname: Shiboski
authors.forename: Sepideh
authors.initials: S
authors.lastname: Farhat
authors.forename: Anna-Barbara
authors.initials: AB
authors.lastname: Moscicki
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D052162:Human papillomavirus 16 / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007113:Immunity, Innate; D016898:Interferon-alpha / Q000378:metabolism; D030361:Papillomavirus Infections / Q000276:immunology / Q000378:metabolism* / Q000821:virology*; D011446:Prospective Studies; D012333:RNA, Messenger / Q000235:genetics; D012142:Respiratory Tract Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000821:virology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D051193:Toll-Like Receptors / Q000378:metabolism*; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000821:virology; D055815:Young Adult
chemical_list: D016898:Interferon-alpha; D012333:RNA, Messenger; D051193:Toll-Like Receptors
references.citation: Curr Protoc Mol Biol. 2006 Feb;Chapter 15:Unit 15.8
references.pmid: 18265376
references.citation: Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
references.pmid: 12184808
references.citation: Vaccine. 2006 Aug 31;24 Suppl 3:S3/26-34
references.pmid: 16950015
references.citation: Nucleic Acids Res. 2006 Jan 1;34(Database issue):D684-8
references.pmid: 16381959
references.citation: Clin Diagn Lab Immunol. 1999 Sep;6(5):751-5
references.pmid: 10473530
references.citation: Nat Immunol. 2000 Nov;1(5):398-401
references.pmid: 11062499
references.citation: Virology. 2009 Feb 20;384(2):410-4
references.pmid: 18986661
references.citation: Gynecol Oncol. 2008 May;109(2 Suppl):S15-21
references.pmid: 18474288
references.citation: J Infect Dis. 2000 Aug;182(2):595-8
references.pmid: 10915094
references.citation: Int Immunol. 2005 Jan;17(1):1-14
references.pmid: 15585605
references.citation: J Infect Dis. 2000 Jun;181(6):1911-9
references.pmid: 10837170
references.citation: AIDS. 2007 Mar 12;21(5):589-98
references.pmid: 17314521
references.citation: J Allergy Clin Immunol. 2003 Feb;111(2):380-8
references.pmid: 12589360
references.citation: Clin Vaccine Immunol. 2008 Jan;15(1):49-54
references.pmid: 17978011
references.citation: J Leukoc Biol. 2007 Sep;82(3):479-87
references.pmid: 17595379
references.citation: Nat Rev Immunol. 2004 Apr;4(4):249-58
references.pmid: 15057783
references.citation: J Immunol. 2005 Jun 15;174(12):7912-9
references.pmid: 15944297
references.citation: Virology. 2005 Jun 20;337(1):76-84
references.pmid: 15914222
references.citation: Nucleic Acids Res. 2007 Jan;35(Database issue):D805-9
references.pmid: 17068075
references.citation: Immunology. 2006 Feb;117(2):220-8
references.pmid: 16423058
references.citation: J Immunol. 2007 Mar 1;178(5):3186-97
references.pmid: 17312167
references.citation: Clin Exp Dermatol. 2002 Oct;27(7):571-7
references.pmid: 12464152
references.citation: Cancer Res. 2004 Aug 15;64(16):5850-60
references.pmid: 15313929
references.citation: Blood. 2006 Jul 15;108(2):544-50
references.pmid: 16537810
references.citation: N Engl J Med. 2003 Feb 6;348(6):518-27
references.pmid: 12571259
references.citation: Front Biosci. 2002 Oct 01;7:d2058-71
references.pmid: 12165480
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1315-20
references.pmid: 14739339
references.citation: J Virol. 2003 Apr;77(8):4588-96
references.pmid: 12663765
references.citation: Appl Environ Microbiol. 2007 Sep;73(18):5731-41
references.pmid: 17644631
references.citation: Clin Cancer Res. 2005 Jul 15;11(14):5273-80
references.pmid: 16033846
references.citation: Int J Gynecol Cancer. 2009 May;19(4):508-12
references.pmid: 19509544
references.citation: Clin Vaccine Immunol. 2008 Jun;15(6):937-45
references.pmid: 18448624
references.citation: Microbes Infect. 2004 Dec;6(15):1388-94
references.pmid: 15596125
references.citation: Semin Immunol. 2007 Feb;19(1):33-40
references.pmid: 17336545
references.citation: J Clin Immunol. 2006 May;26(3):222-32
references.pmid: 16783462
references.citation: J Virol. 2002 Sep;76(17):8729-36
references.pmid: 12163593
references.citation: J Pathol. 1999 Sep;189(1):12-9
references.pmid: 10451482
references.citation: Clin Vaccine Immunol. 2008 Sep;15(9):1369-73
references.pmid: 18632922
references.citation: J Natl Cancer Inst. 1995 Jun 7;87(11):796-802
references.pmid: 7791229
references.citation: J Pediatr. 1998 Feb;132(2):277-84
references.pmid: 9506641
references.citation: J Virol. 2006 May;80(9):4286-91
references.pmid: 16611887
references.citation: Vaccine. 2006 Mar 30;24 Suppl 1:S16-22
references.pmid: 16219398